regenerative medicine News
-
Minaris Regenerative Medicine Strengthens Global and Regional Leadership
Minaris Regenerative Medicine is pleased to announce new appointments to strengthen its global and regional leadership. Minaris Regenerative Medicine, having facilities in the U.S., Germany, and Japan, will shift to a model of regional operational leadership on October 1, 2021. Under the new model, its three regional Chief Operating Officers (COOs) will collaborate on a Global Functional team to ...
-
Minaris Regenerative Medicine Appoints Hiroto Bando as New General Manager
Minaris Regenerative Medicine is pleased to announce new appointments to strengthen its global and regional leadership. Hiroto Bando, PhD, who joined Minaris Regenerative Medicine as Deputy General Manager, Regenerative Medicine Business Sector (RMBS), Showa Denko Materials Co., Ltd., in November 2020, will become General Manager, RMBS as well as President and Chief Executive Officer of Minaris ...
-
Cell Therapy Re-brands as Celixir
Celixir, a leading British biotechnology company delivering breakthrough regenerative medicines, has today rebranded from Cell Therapy. The change reflects the company’s continued commitment to discovering, developing and delivering life-altering regenerative medicines, and transforming patient care. “The name Celixir combines ‘Cell’ with the Latin root word elixir to ...
By Celixir plc
-
Regenerative Medicine
Regenerative medicine is the use of tissue engineering and molecular biology to improve or replace biological function in human cells, tissues and organs. Research on adult stem cells has generated a great deal of excitement in this regard. Despite the challenges in understanding adult stem cell biology, the field of regenerative medicine is taking shape. Developers, FDA regulators ...
-
Dutch Secretary of State visits Xeltis following RegMedXB funding
The Dutch State Secretary visited Xeltis today following the recent decision of the Government to provide funding to the RegMedXB partnership, of which Xeltis is one of the industrial partners. Minister Mona Keijzer met executives from the RegMedXB private-public partnership, which recently secured funding for up to €56 million from the Dutch National Growth Fund to build an infrastructure ...
By XELTIS BV
-
BlueRock Therapeutics to Present at 2019 Cell & Gene Meeting on the Mediterranean
BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel CELL+GENE™ platform to develop regenerative medicines for intractable diseases, today announced its participation in the inaugural Cell & Gene Meeting on the Mediterranean to be held April 23-25 in Barcelona, Spain. Emile Nuwaysir, Ph.D., President and Chief Executive Officer of BlueRock, and Vice ...
-
First Australian regenmed delegation welcomed to Toronto
The world-renowned MaRS Discovery District in the health precinct associated with the University of Toronto is the worlds largest urban innovation hub boasting tenants such as Facebook, JLABS, Autodesk and a host of biotech and medtech startups. The CCRM Australia delegation was warmly recognised and welcomed in official speeches at the opening and invited to connect with parliamentarians, major ...
-
Aspect Biosystems To Present At 2021 Cell & Gene Meeting On The Mesa
Vancouver, BC, Canada, October 4, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, has announced that President & CEO Tamer Mohamed will present at the annual Cell & Gene Meeting on the Mesa to be held October 12-14, 2021 in Carlsbad, CA. This is the third time that the company will be presenting at this ...
-
Aspect Biosystems to Present at 2020 Virtual Cell & Gene Meeting on The Mesa
Aspect Biosystems announced today that Tamer Mohamed, Chief Executive Officer, will present at the annual Cell & Gene Meeting on the Mesa to be held virtually October 12-16, 2020. This is the second time that Aspect Biosystems will be presenting at this conference. Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a five-day virtual conference ...
-
Minaris will be the commercial manufacturer in Europe for Skysona™, bluebird bio`s gene therapy for CALD
Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry, will be the commercial manufacturer in Europe for SkysonaTM (elivaldogene autotemcel, Lenti-D™), a product of bluebird bio, Inc. Today, the European Commission (EC) has granted marketing authorization for SkysonaTM, the ...
-
European Biotech Week: Holostem virtually opens its doors to the public
Modena, September 27th, 2021 – On October 1st, Holostem Terapie Avanzate and the Centre for Regenerative Medicine “Stefano Ferrari” at the University of Modena and Reggio Emilia – in collaboration with the “Le Ali di Camilla” Association – will organise a virtual tour of their laboratories in Modena. HoloTour will take the public inside state-of-the-art ...
-
Aspect Biosystems And Jsr Corporation Enter Collaboration To Develop Bioprinted Vascularized Tissues For Regenerative Medicine
Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation. This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary microfluidic 3D ...
-
European Biotech Week and Emilia-Romagna Open: Open Day
Modena, September 20, 2019 – During EUROPEAN BIOTECH WEEK and EMILIA-ROMAGNA OPEN Event, Friday 27 September 2019 Holostem will open its doors to the city with two events: Open Day from 15:00 to 17:00 for the discovery of stem cells and their clinical application for the treatment of rare diseases without therapeutic alternatives. Citizens will be able to visit the research laboratories of ...
-
BlueRock Therapeutics to Participate at Upcoming Conferences
BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel CELL+GENE™ platform to develop regenerative medicines for intractable diseases, today announced that the company will present at the following upcoming conferences. Presentation details are as follows: BIO International Convention Corporate Presentation Date: Tuesday, June 4, 2019 Time: 2:15 p.m. EDT ...
-
Welcome Emmanuelle Bommier, Senior Director, Business Development, to Minaris Regenerative Medicine (United States)
Minaris Regenerative Medicine (United States) welcomes Emmanuelle Bommier in the role of Senior Director, Business Development, effective August 30, 2021. In her role as head of business development for North America, reporting to CEO, Dr. Kazuchika Furuishi, Emmanuelle will be accountable for creating new business opportunities and client management for Minaris in the United States, as well as ...
-
BlueRock Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa
BlueRock Therapeutics, today announced that Emile Nuwaysir, Ph.D., Chief Executive Officer of BlueRock and Vice Chairman of the Alliance for Regenerative Medicine (ARM), will present at the Cell & Gene Meeting on the Mesa, to be held Oct. 2-4 in Carlsbad, Calif. The following are specific details regarding BlueRock’s participation at the conference: Event: BlueRock Therapeutics ...
-
Regenerative Medicine Made In Italy
Fortunately, not all brains are fleeing Italy. And when they come together the result is very often of excellence. A striking example is the TMR (registered trademark and acronym of Magnetic Resonance Therapeutic), an innovative medical device that provides great benefits for our health and well-being. The TMR is a 100% Made in Italy device, made by the Thereson company, the result of a long ...
-
Aziyo Biologics to Present at the H.C. Wainwright Bioconnect Virtual Conference
Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that members of management will present at the upcoming H.C. Wainwright Bioconnect Virtual Conference. A Pre-recorded presentation will be available on Monday, January 10th ...
-
Aziyo Biologics to Participate in the Cowen 42nd Annual Health Care Conference
Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming 42nd Annual Cowen Health Care Conference. Date: Wednesday, March 9, 2022 Format: Fireside chat and 1×1 meetings The ...
-
AVITA Medical to Announce First Quarter 2022 Financial Results
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it will release its first quarter 2022 financial results on Thursday, May 12, 2022. In conjunction with such release, the Company plans to host a conference ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you